{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:11:05Z","timestamp":1793387465533,"version":"4.5.0"},"reference-count":134,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T00:00:00Z","timestamp":1515715200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research (NIHR) Biomedical Research Centre at South London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Maudsley NHS Foundation Trust"},{"DOI":"10.13039\/100009360","name":"King's College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009360","id-type":"DOI","asserted-by":"publisher"}]},{"name":"UK Medical Research Council","award":["MR\/J00460X\/1"],"award-info":[{"award-number":["MR\/J00460X\/1"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.neuropharm.2017.12.040","type":"journal-article","created":{"date-parts":[[2017,12,25]],"date-time":"2017-12-25T15:05:46Z","timestamp":1514214346000},"page":"200-218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":315,"special_numbering":"C","title":["Psychiatry & the psychedelic drugs. Past, present & future"],"prefix":"10.1016","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4647-8088","authenticated-orcid":false,"given":"James J.H.","family":"Rucker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2154-2293","authenticated-orcid":false,"given":"Jonathan","family":"Iliff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Nutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2017.12.040_bib1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s12231-011-9152-5","article-title":"A\u00a0prehistoric mural in Spain depicting neurotropic psilocybe mushrooms?","volume":"65","author":"Akers","year":"1992","journal-title":"Econ. Bot."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1176\/ajp.125.3.341","article-title":"Chronic users of LSD: the \"acidheads\"","volume":"125","author":"Blacker","year":"1968","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib3","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib4","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0893-133X(95)00145-4","article-title":"Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans","volume":"14","author":"Bonson","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0166-4328(96)00102-7","article-title":"Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium","volume":"73","author":"Bonson","year":"1996","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib6","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00005053-197002000-00003","article-title":"Lysergic acid diethylamide as a variable in the hospital treatment of alcoholism: a follow-up study","volume":"150","author":"Bowen","year":"1970","journal-title":"J.\u00a0Nerv. Ment. Dis."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib7","article-title":"Dronabinol for chemotherapy-induced nausea and vomiting unresponsive to antiemetics","volume":"49","author":"Brafford May","year":"2016","journal-title":"CMAR"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib8","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/S0140-6736(02)08701-9","article-title":"Mescaline use for 5700 years","volume":"359","author":"Bruhn","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib9","series-title":"Goodman and Gilman's the Pharmacological Basis of Therapeutics","author":"Brunton","year":"2011"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib10","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/ijnp\/pyx011","article-title":"5-HT2A agonists: a novel therapy for functional neurological disorders?","volume":"20","author":"Bryson","year":"2017","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib11","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0014-2999(85)90407-8","article-title":"Daily LSD administration selectively decreases serotonin2 receptor binding in rat brain","volume":"109","author":"Buckholtz","year":"1985","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib12","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/00004714-200008000-00006","article-title":"Weekly dosing of fluoxetine for the continuation phase of treatment of major depression: results of a placebo-controlled, randomized clinical trial","volume":"20","author":"Burke","year":"2000","journal-title":"J.\u00a0Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib13","first-page":"241","article-title":"L.S.D. 25 as an aid in psychotherapy; preliminary report of a new drug","volume":"11","author":"Busch","year":"1950","journal-title":"Dis. Nerv. Syst."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib14","first-page":"1","article-title":"Psilocybin with psychological support for treatment-resistant depression: six-month follow-up","volume":"29","author":"Carhart-Harris","year":"2017","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib15","first-page":"619","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib16","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1073\/pnas.1119598109","article-title":"Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin","volume":"109","author":"Carhart-Harris","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib17","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.1073\/pnas.1518377113","article-title":"Neural correlates of the LSD experience revealed by multimodal neuroimaging","volume":"113","author":"Carhart-Harris","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib18","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1080\/02791072.2013.825034","article-title":"Experienced drug users assess the relative harms and benefits of drugs: a web-based survey","volume":"45","author":"Carhart-Harris","year":"2013","journal-title":"J.\u00a0Psychoact. Drugs"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib19","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00213-007-0930-9","article-title":"Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans","volume":"195","author":"Carter","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib20","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1001\/archpsyc.1960.03590090042008","article-title":"Lysergic acid diethylamide (LSD-25) as a facilitating agent in psychotherapy","volume":"2","author":"Chandler","year":"1960","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib21","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/00005053-195509000-00001","article-title":"Clinical reactions and tolerance to LSD in chronic schizophrenia","volume":"122","author":"Cholden","year":"1955","journal-title":"J.\u00a0Nerv. Ment. Dis."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib22","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/00005053-196001000-00005","article-title":"Lysergic acid diethylamide: side effects and complications","volume":"130","author":"Cohen","year":"1960","journal-title":"J.\u00a0Nerv. Ment. Dis."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib23","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1001\/archpsyc.1963.01720110051006","article-title":"Prolonged adverse reactions to lysergic acid diethylamide","volume":"8","author":"Cohen","year":"1963","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib24","series-title":"COMPASS - Navigating Mental Health Pathways","author":"COMPASS - Navigating Mental Health Pathways [WWW Document]","year":"2017"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib25","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1177\/0269881109103227","article-title":"Neuronal correlates of visual and auditory alertness in the DMT and ketamine model of psychosis","volume":"24","author":"Daumann","year":"2010","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib26","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/BF01567467","article-title":"Studies on mescaline I. Action in schizophrenic patients","volume":"29","author":"Denber","year":"1955","journal-title":"Psychiatr. Q."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib27","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/00005053-195812000-00006","article-title":"Psychotherapy with lysergic acid diethylamide","volume":"127","author":"Eisner","year":"1958","journal-title":"J.\u00a0Nerv. Ment. Dis."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib28","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(01)95215-8","article-title":"A\u00a0note on the phenomena of mescal intoxication","volume":"149","author":"Ellis","year":"1897","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/02791072.2014.877321","article-title":"History and future of the multidisciplinary association for psychedelic studies (MAPS)","volume":"46","author":"Emerson","year":"2014","journal-title":"J.\u00a0Psychoact. Drugs"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib30","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/08039488.2017.1336252","article-title":"Lessons to be learned from early psychedelic therapy in Denmark","volume":"71","author":"Erritzoe","year":"2017","journal-title":"Nord. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib31","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.drugalcdep.2010.03.024","article-title":"Assessment of addiction severity among ritual users of ayahuasca","volume":"111","author":"F\u00e1bregas","year":"2010","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib32","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1360-0443.2006.01652.x","article-title":"Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids","volume":"102","author":"Gable","year":"2007","journal-title":"Addiction"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib33","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1360-0443.2004.00744.x","article-title":"Comparison of acute lethal toxicity of commonly abused psychoactive substances","volume":"99","author":"Gable","year":"2004","journal-title":"Addiction"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib34","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","article-title":"Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases","volume":"202","author":"Gasser","year":"2014","journal-title":"J.\u00a0Nerv. Ment. Dis."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib35","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0269881114555249","article-title":"LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects","volume":"29","author":"Gasser","year":"2015","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib36","doi-asserted-by":"crossref","first-page":"i6067","DOI":"10.1136\/bmj.i6067","article-title":"The war on drugs has failed: doctors should lead calls for drug policy reform","volume":"355","author":"Godlee","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib37","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1055\/s-2005-916185","article-title":"Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers","volume":"38","author":"Gouzoulis-Mayfrank","year":"2005","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib38","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4088\/JCP.14m09298","article-title":"The economic burden of adults with major depressive disorder in the United States (2005 and 2010)","volume":"76","author":"Greenberg","year":"2015","journal-title":"J.\u00a0Clin. Psychiatr."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib39","first-page":"405","article-title":"The economic burden of depression in 1990","volume":"54","author":"Greenberg","year":"1993","journal-title":"J.\u00a0Clin. Psychiatr."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib40","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1177\/0269881108094300","article-title":"Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later","volume":"22","author":"Griffiths","year":"2008","journal-title":"J.\u00a0Psychopharmacol. (Oxf.)"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib41","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib42","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","article-title":"Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance","volume":"187","author":"Griffiths","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib43","first-page":"275","article-title":"The psychedelic drug therapies","volume":"20","author":"Grinspoon","year":"1981","journal-title":"Curr. Psychiatr. Ther."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib44","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer","volume":"68","author":"Grob","year":"2011","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib45","first-page":"203","article-title":"Artificial psychoses produced by mescaline","volume":"82","author":"Guttmann","year":"1936","journal-title":"Br. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib46","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0376-8716(02)00306-X","article-title":"Hallucinogen persisting perception disorder: what do we know after 50 years?","volume":"69","author":"Halpern","year":"2003","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib47","series-title":"Chasing the Scream: the First and Last Days of the War on Drugs","author":"Hari","year":"2015"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib48","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1192\/bjp.170.3.205","article-title":"Suicide as an outcome for mental disorders. A meta-analysis","volume":"170","author":"Harris","year":"1997","journal-title":"Br. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib49","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1177\/0269881113513851","article-title":"Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision","volume":"28","author":"Hendricks","year":"2014","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib50","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1177\/0269881114565653","article-title":"Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population","volume":"29","author":"Hendricks","year":"2015","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib51","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1055\/s-2007-979352","article-title":"Blood flow and cerebral laterality in the mescaline model of psychosis","volume":"31","author":"Hermle","year":"1998","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib52","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1176\/ajp.108.8.579","article-title":"Effects of mescaline and lysergic acid (d-LSD-25)","volume":"108","author":"Hoch","year":"1952","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib53","series-title":"LSD: My Problem Child","author":"Hofmann","year":"2013"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib54","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hlca.19590420518","article-title":"Psilocybin und Psilocin, zwei psychotrope Wirkstoffe aus mexikanischen Rauschpilzen","volume":"42","author":"Hofmann","year":"1959","journal-title":"Helv. Chim. Acta"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib55","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1176\/ajp.125.10.1352","article-title":"A\u00a0controlled comparison of lysergic acid diethylamide (LSD) and dextroamphetmine in alcoholics","volume":"125","author":"Hollister","year":"1969","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib56","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.yebeh.2015.04.009","article-title":"Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: a potential role for infantile spasms and Lennox\u2013Gastaut syndrome","volume":"47","author":"Hussain","year":"2015","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib57","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1001\/archneurpsyc.1956.02330290012002","article-title":"Studies on lysergic acid diethylamide (LSD-25): 1. Effects in former morphine addicts and development of tolerance during chronic intoxication","volume":"76","author":"Isbell","year":"1956","journal-title":"AMA Arch. Neur. Psych."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib58","doi-asserted-by":"crossref","first-page":"315","DOI":"10.15288\/qjsa.1962.23.315","article-title":"A\u00a0treatment program for alcoholics in a mental hospital","volume":"23","author":"Jensen","year":"1962","journal-title":"Q.\u00a0J. Stud. Alcohol"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib59","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1177\/0269881114568039","article-title":"Psychedelics not linked to mental health problems or suicidal behavior: a population study","volume":"29","author":"Johansen","year":"2015","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib60","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: guidelines for safety","volume":"22","author":"Johnson","year":"2008","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib61","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib62","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1007\/s00213-015-4014-y","article-title":"LSD enhances the emotional response to music","volume":"232","author":"Kaelen","year":"2015","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib63","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.euroneuro.2016.03.018","article-title":"LSD modulates music-induced imagery via changes in parahippocampal connectivity","volume":"0","author":"Kaelen","year":"2016","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib64","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1176\/ajp.123.7.884","article-title":"Suicide during an LSD reaction","volume":"123","author":"Keeler","year":"1967","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib65","doi-asserted-by":"crossref","first-page":"502","DOI":"10.2307\/1414910","article-title":"Mescal visions and eidetic vision","volume":"37","author":"Kluver","year":"1926","journal-title":"Am. J. Psychol."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib66","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/00005053-191307000-00001","article-title":"A\u00a0preliminary note on the psychic action of mescalin, with special reference to the mechanism of visual hallucinations","volume":"40","author":"Knauer","year":"1913","journal-title":"J.\u00a0Nerv. Ment. Dis."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib67","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.biopsych.2012.04.005","article-title":"Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors","volume":"72","author":"Kometer","year":"2012","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib68","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063972","article-title":"Psychedelics and mental health: a population study","volume":"8","author":"Krebs","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib69","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.2-98.v1","article-title":"Over 30 million psychedelic users in the United States","author":"Krebs","year":"2013","journal-title":"F1000Res."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib70","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1177\/0269881112439253","article-title":"Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials","volume":"26","author":"Krebs","year":"2012","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2377-9-59","article-title":"Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review","volume":"9","author":"Lakhan","year":"2009","journal-title":"BMC Neurol."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib72","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00005053-196808000-00008","article-title":"Lysergic acid diethylamide (LSD-25) and schizophrenic reactions","volume":"147","author":"Langs","year":"1968","journal-title":"J.\u00a0Nerv. Ment. Dis."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib73","first-page":"1","article-title":"Neurotoxicity and LSD treatment: a follow-up study of 151 patients in Denmark","author":"Larsen","year":"2016","journal-title":"Hist. Psychiatr."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib74","series-title":"Acid Dreams","author":"Lee","year":"2007"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib75","series-title":"Shroom","author":"Letcher","year":"2008"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib76","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/jnnp.16.1.7","article-title":"The effects of methedrine and of lysergic acid diethylamide on mental processes and on the blood adrenaline level","volume":"16","author":"Liddell","year":"1953","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatr."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib77","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/3218","article-title":"The global burden of disease, 1990-2020","volume":"4","author":"Lopez","year":"1998","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib78","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1176\/ajp.126.1.59","article-title":"A\u00a0clinical study of LSD treatment in alcoholism","volume":"126","author":"Ludwig","year":"1969","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib79","doi-asserted-by":"crossref","first-page":"34","DOI":"10.15288\/qjsa.1961.22.034","article-title":"The use of LSD-25 in the treatment of alcoholism and other psychiatric problems","volume":"22","author":"Maclean","year":"1961","journal-title":"Q.\u00a0J. Stud. Alcohol"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib80","series-title":"PAYING THE PRICE: the Cost of Mental Health Care in England to 2026","author":"McCrone","year":"2008"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib81","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0378-8741(84)90003-5","article-title":"Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and beta-carboline constituents of ayahuasca","volume":"10","author":"McKenna","year":"1984","journal-title":"J.\u00a0Ethnopharmacol."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib82","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/00005053-195707000-00014","article-title":"The effects of mescaline sulfate in chronic schizophrenia","volume":"125","author":"Merlis","year":"1957","journal-title":"J.\u00a0Nerv. Ment. Dis."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib83","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1136\/bmj.2.1875.1625","article-title":"Remarks on the effects of anhelonium lewinii (the mescal button)","volume":"2","author":"Mitchell","year":"1896","journal-title":"Br. Med. J."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib84","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","article-title":"Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder","volume":"67","author":"Moreno","year":"2006","journal-title":"J.\u00a0Clin. Psychiatr."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib85","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/j.1360-0443.1994.tb02787.x","article-title":"The generalizability of the dependence syndrome across substances: an examination of some properties of the proposed DSM-IV dependence criteria","volume":"89","author":"Morgenstern","year":"1994","journal-title":"Addiction"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib86","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0140-6736(07)61415-9","article-title":"Depression, chronic diseases, and decrements in health: results from the World Health Surveys","volume":"370","author":"Moussavi","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib87","doi-asserted-by":"crossref","DOI":"10.1176\/ajp.156.7.1000","article-title":"Recurrence after recovery from major depressive disorder during 15 years of observational follow-up","author":"Mueller","year":"1999","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib88","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/S0140-6736(96)07495-8","article-title":"Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study","volume":"349","author":"Murray","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib89","doi-asserted-by":"crossref","first-page":"15171","DOI":"10.1523\/JNEUROSCI.2063-13.2013","article-title":"Broadband cortical desynchronization underlies the human psychedelic state","volume":"33","author":"Muthukumaraswamy","year":"2013","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib90","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1080\/02791072.2014.873688","article-title":"The heffter research Institute: past and hopeful future","volume":"46","author":"Nichols","year":"2014","journal-title":"J.\u00a0Psychoact. Drugs"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib91","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrn3530","article-title":"Effects of Schedule I drug laws on neuroscience research and treatment innovation","volume":"14","author":"Nutt","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib92","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S0140-6736(10)61462-6","article-title":"Drug harms in the UK: a multicriteria decision analysis","volume":"376","author":"Nutt","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib93","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/jhmas\/jrs050","article-title":"Efficacy and enlightenment: LSD psychotherapy and the drug amendments of 1962","volume":"69","author":"Oram","year":"2012","journal-title":"J.\u00a0Hist. Med. Allied Sci."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib94","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1749-6632.1957.tb40738.x","article-title":"A\u00a0review of the clinical effects of psychotomimetic agents","volume":"66","author":"Osmond","year":"1957","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib95","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1590\/1516-4446-2014-1496","article-title":"Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report","volume":"37","author":"Os\u00f3rio","year":"2015","journal-title":"Rev. Bras. Psiquiatr."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib96","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1358\/dot.2008.44.3.1162240","article-title":"Sodium oxybate: efficacy, safety and tolerability in the treatment of narcolepsy with or without cataplexy","volume":"44","author":"Owen","year":"2008","journal-title":"Drugs Today"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib97","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1001\/jama.1970.03170240060010","article-title":"The experimental use of psychedelic (LSD) psychotherapy","volume":"212","author":"Pahnke","year":"1970","journal-title":"JAMA"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib98","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0118143","article-title":"The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network","volume":"10","author":"Palhano-Fontes","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib99","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/00005053-195402000-00001","article-title":"Clinical reactions of schizophrenics to sodium amytal, pervitin hydrochloride, mescaline sulfate, and d-lysergic acid diethylamide (LSD25)","volume":"119","author":"Pennes","year":"1954","journal-title":"J.\u00a0Nerv. Ment. Dis."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib100","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1192\/bjp.bp.109.068452","article-title":"The psychiatric case register: noble past, challenging present, but exciting future","volume":"195","author":"Perera","year":"2009","journal-title":"BJP"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib101","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1177\/0022167817711304","article-title":"Developing guidelines and competencies for the training of psychedelic therapists","volume":"57","author":"Phelps","year":"2017","journal-title":"J.\u00a0Humanist. Psychol."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib102","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.cub.2016.12.030","article-title":"The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation","volume":"27","author":"Preller","year":"2017","journal-title":"Curr. Biol."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib103","first-page":"577","article-title":"Anhalonium lewinii (mescal buttons)","volume":"11","author":"Prentiss","year":"1895","journal-title":"Ther. Gaz."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib104","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/jat\/9.4.183","article-title":"A\u00a0mescaline associated fatality","volume":"9","author":"Reynolds","year":"1985","journal-title":"J.\u00a0Anal. Toxicol."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib105","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000077946","article-title":"Effects of the South American psychoactive beverage ayahuasca on regional brain electrical activity in humans: a functional neuroimaging study using low-resolution electromagnetic tomography","volume":"50","author":"Riba","year":"2004","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib106","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00213-006-0358-7","article-title":"Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant","volume":"186","author":"Riba","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib107","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib108","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1177\/0269881116679368","article-title":"Psychedelics in the treatment of unipolar mood disorders: a systematic review","volume":"30","author":"Rucker","year":"2016","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib109","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/JCP.0000000000000436","article-title":"Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a SPECT study","volume":"36","author":"Sanches","year":"2016","journal-title":"J.\u00a0Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib110","first-page":"491","article-title":"The therapeutic value of lysergic acid diethylamide in mental illness","volume":"100","author":"Sandison","year":"1954","journal-title":"J.\u00a0Ment. Sci."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib111","first-page":"332","article-title":"Further studies in the therapeutic value of lysergic acid diethylamide in mental illness","volume":"103","author":"Sandison","year":"1957","journal-title":"Br. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib112","first-page":"59","article-title":"The effectiveness of psychedelic (LSD) therapy: a preliminary report","volume":"2","author":"Savage","year":"1967","journal-title":"Br. J. Soc. Psychol."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib113","series-title":"Plants of the Gods","author":"Schultes","year":"1979"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib114","first-page":"1163","article-title":"Psychedelic drugs as therapeutics: No illusions about the challenges","volume":"30","author":"Sellers","year":"2017","journal-title":"Clin. Pharmacol. Therapeut."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib115","doi-asserted-by":"crossref","first-page":"469","DOI":"10.15288\/qjsa.1966.27.469","article-title":"A\u00a0controlled study of lysergide in the treatment of alcoholism. 1. The effects on drinking behavior","volume":"27","author":"Smart","year":"1966","journal-title":"Q.\u00a0J. Stud. Alcohol"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib116","series-title":"Peyote Religion","author":"Stewart","year":"1987"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib117","doi-asserted-by":"crossref","DOI":"10.1186\/1471-244X-9-51","article-title":"The South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLAM BRC) case register: development and descriptive data","volume":"9","author":"Stewart","year":"2009","journal-title":"BMC Psychiatr."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib118","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/BF00427959","article-title":"Effect of chronic antidepressant treatment and subsequent withdrawal on [3H]-5-hydroxytryptamine and [3H]-spiperone binding in rat frontal cortex and serotonin receptor mediated behaviour","volume":"80","author":"Stolz","year":"1983","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib119","first-page":"241","article-title":"Human hallucinogen interactions with drugs affecting serotonergic neurotransmission","volume":"7","author":"Strassman","year":"1992","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib120","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/00005053-198410000-00001","article-title":"Adverse reactions to psychedelic drugs. A review of the literature","volume":"172","author":"Strassman","year":"1984","journal-title":"J.\u00a0Nerv. Ment. Dis."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib121","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1001\/archpsyc.1994.03950020009001","article-title":"Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects","volume":"51","author":"Strassman","year":"1994","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib122","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1177\/0269881110382466","article-title":"Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies","volume":"25","author":"Studerus","year":"2011","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib123","doi-asserted-by":"crossref","first-page":"932","DOI":"10.15288\/qjsa.1970.31.932","article-title":"Lysergide treatment of schizophrenic and nonschizophrenic alcoholics: a controlled evaluation","volume":"31","author":"Tomsovic","year":"1970","journal-title":"Q.\u00a0J. Stud. Alcohol"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib124","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.euroneuro.2016.03.012","article-title":"Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans","volume":"0","author":"Valle","year":"2016","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib125","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0165-0327(03)00168-X","article-title":"Family caregiving in depression: impact on caregivers' daily life, distress, and help seeking","volume":"81","author":"van Wijngaarden","year":"2004","journal-title":"J.\u00a0Affect. Disord."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib126","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0893-133X(96)00246-1","article-title":"Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis","volume":"16","author":"Vollenweider","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib127","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","article-title":"Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action","volume":"9","author":"Vollenweider","year":"1998","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib128","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1177\/0269881116642538","article-title":"Hallucinogen use and intimate partner violence: prospective evidence consistent with protective effects among men with histories of problematic substance use","volume":"30","author":"Walsh","year":"2016","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib129","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/mpr.139","article-title":"The economic burden of depression and the cost-effectiveness of treatment","volume":"12","author":"Wang","year":"2003","journal-title":"Int. J. Meth. Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib130","series-title":"The Road to Eleusis","author":"Wasson","year":"2008"},{"key":"10.1016\/j.neuropharm.2017.12.040_bib131","doi-asserted-by":"crossref","first-page":"5","DOI":"10.5694\/j.1326-5377.1964.tb133752.x","article-title":"Lysergic acid diethylamide in psychotherapy. Part I: clinical aspects","volume":"1","author":"Whitaker","year":"1964","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib132","doi-asserted-by":"crossref","first-page":"36","DOI":"10.5694\/j.1326-5377.1964.tb133783.x","article-title":"Lysergic acid diethylamide in psychotherapy. Part II: results","volume":"1","author":"Whitaker","year":"1964","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib133","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/0269881113513852","article-title":"Dimethyltryptamine (DMT): prevalence, user characteristics and abuse liability in a large global sample","volume":"28","author":"Winstock","year":"2013","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.12.040_bib134","series-title":"World Health Organisation","author":"World Health Organisation [WWW Document]","year":"2017"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839081730638X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839081730638X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T06:00:16Z","timestamp":1660197616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002839081730638X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":134,"alternative-id":["S002839081730638X"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.12.040","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psychiatry & the psychedelic drugs. Past, present & future","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.12.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}